Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Japanese pharmaceutical company Daiichi Sankyo has signed a basic agreement with the University of Tokyo, Nichi-Iko Pharmaceutical and RIKEN for the research and development (R&D) of a Nafamostat inhalation formulation to treat Covid-19.
Nafamostat is an injectable drug indicated in Japan for the treatment for acute pancreatitis and disseminated intravascular coagulation.
According to the data available so far, the drug is adequately safe. During the first stage of Covid-19 infection, the outer enveloped of SARS-CoV-2 fuses with the host cell surface membrane.